Breakout Session: How to Access Non-Traditional Financing

3:00 PM - 4:00 PM
Rooms 146B & 146C

Following panel 3, this breakout session will inform industry participants about where and how to access funding for neglected disease R&D. The session will be moderated by David Perry, CEO of Anacor Pharmaceuticals, who will ask the "hard questions" of government, foundation, and PDP funders about how to access the funding opportunities in this space.


  • Moderator: David Perry, CEO, Anacor Pharmaceuticals
  • Michael Kurrila, Director, Division of Office of BioDefense Research Affairs, NIH/NIAID
  • Robert C. Lorette, Senior Vice President, Business Development, Global Alliance for TB Drug Development
  • Jean-Pierre Paccaud, VP, Business Development, Drugs for Neglected Diseases initiative
  • John Schaetzl, Consultant to the Bill & Melinda Gates Foundation

Who's Who



Michael Kurrila - Dr. Kurilla is the Director of the Office of Biodefense Research Affairs and Associate Director for Biodefense Product Development for the National Institute of Allergy and Infectious Diseases (NIAID). His primary role is to provide overall institute coordination for product development of medical countermeasures against bioterror threats. He received his undergraduate degree in chemistry from the California Institute of Technology. He earned his MD-PhD from Duke University. He took his postgraduate medical training in Pathology at the Brigham & Women’s Hospital in Boston, MA and a postdoctoral fellowship with Dr. Elliott Kieff at Harvard Medical School as a Life Sciences Research Foundation Fellow followed by a Markey Scholar Award. At the University of Virginia, he was an Assistant Professor of Pathology as well as Co-Director of the Laboratory of Molecular Diagnostics and Associate Director for Clinical Microbiology. He moved to the private sector working in anti-infective drug development at Dupont Pharmaceuticals, Bristol-Myers Squibb, and Wyeth. He subsequently joined the National Institute of Allergy and Infectious Diseases (NIAID) as a Medical Officer. In 2005, he was named to his current positions within NIAID.

Lorette Robert Lorette - Robert C. Lorette, Esq. is Senior Vice President of Business Development for the TB Alliance. In this role, Mr. Lorette helps lead the TB Alliance’s efforts to establish agreements and strategic alliances within the context of the product development partnership (PDP) business model, and thus play an integral role in achieving the portfolio development and related resource mobilization goals of the TB Alliance.

Before joining the TB Alliance, Mr. Lorette founded and was President and CEO of Boston Life Science Advisors, a corporate development consulting firm dedicated to serving biotech, medical device and other life science organizations. He also co-founded and served as Managing Director of Transform Ventures LLC, a firm that brings capital, executive leadership, and engineering and manufacturing resources together to rapidly advance medical device technologies to a significant value inflection point.

Before founding these two companies, Mr. Lorette served as Chief Business Officer and Senior Vice President of Dynogen Pharmaceuticals, Inc., a clinical-stage drug development company focusing on gastrointestinal and genitourinary disorders. Earlier in his career, Mr. Lorette served in various management, corporate development, and legal roles for organizations such as Boston Healthcare Associates, Inc., UroMed Corporation, and Bausch & Lomb Incorporated.

Mr. Lorette received his law degree from Syracuse University College of Law and is admitted to practice law in Massachusetts, Connecticut, and New York. Additional accreditations include a Masters in Public Administration from the Maxwell School of Syracuse University and a Bachelor’s degree in economics from the College of the Holy Cross. Mr. Lorette also attended the Program for Management Development at the Harvard Business School.
  Jean-Pierre Paccaud - Dr. Paccaud is responsible for DNDi’s business development activities, including opportunity identification, contract structure and negotiations, and alliance management. Prior to joining DNDi, he served as Head of Business Development for R&D products at OM Pharma.

Dr. Paccaud also notably founded and led Athelas SA, a startup company active in the field of anti-bacterial drug discovery, until its merger with Merlion Pharmaceuticals. Before taking on entrepreneurial challenges in industry, Dr. Paccaud spent more than 15 years in academia, working in immunology, diabetes, and cell biology.

Trained as a molecular and cellular biologist, Jean-Pierre Paccaud completed his post-doctoral studies at the University of California at Berkeley, and earned his PhD at the University of Geneva School of Medicine.

David Perry - David P. Perry, has served as Anacor's President and Chief Executive Officer since March 2002 and has been a member of the board of directors since April 2002. In 1997, Mr. Perry founded Chemdex Corporation, which was acquired by NexPrise, Inc., a business-to-business marketplace company that focused on the life-sciences industry, and until November 2001 served as its Chief Executive Officer. In 1995, Mr. Perry co-founded Virogen, a biotech company based in Boston. Mr. Perry is on the board of the Infectious Disease Research Institute, a nonprofit global health research center.  Mr. Perry has a B.S. from the University of Tulsa and an M.B.A. from Harvard Business School.


John Schaetzl - John is an independent consultant health care investor, analyst and manger with broad and deep  experience in several organizational settings. He is currently employed in several advisory roles. He is also the Lead Non-Executive Director at SustainAbility LTD, a global think tank and consultancy where he is  responsible for monitoring fulfillment of SustainAbility’s triple bottom line charter and hybrid structure.

In addition to advising the Bill and Melinda Gates Foundation , John advises other  foundations and government agencies as  well as venture capital and institutional fund managers on investments which support sustainable  outcomes in global health access and economic development in emerging markets. He is on the Board of  Columbus House Inc and the Interim Board of the Oxford Lotus Health Fund.  He has participated in  four Phama Futures Workshops multi year dialogs between pharmaceutical industry execs and institutional investors.  

John retired from General Electric Asset management after a decade of healthcare investing. Prior to that  he was an executive with Bayer Pharmaceuticals, a consultant to the pharmaceutical industry and a  University teacher and administrator. John is the co-author of Practical Politics and American Government  (McMillan) and Project 18: Effectively Educating Young Voters (Edinboro).